Blinatumomab (Blincyto®) has received accelerated approval for treatment of relapsed or refractory acute lymphoblastic leukemia. This article describes the authors’ experience with a multidisciplinary collaboration among nursing, pharmacy, prescribers, and support staff, which has proven to be key for safe administration. The approach can be applied to other institutions planning to use blinatumomab.
At a Glance
- Blinatumomab is a therapy with many complexities regarding preparation, administration, monitoring, and coordination of care, which may pose challenges for successful implementation.
- Institutional blinatumomab guidelines and order sets serve as essential resources for the multidisciplinary team throughout the treatment process.
- A collaborative approach with a multidisciplinary team is needed for the safe administration of blinatumomab.